180 related articles for article (PubMed ID: 24089344)
1. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
Agarwal A; Chang GJ; Hu CY; Taggart M; Rashid A; Park IJ; You YN; Das P; Krishnan S; Crane CH; Rodriguez-Bigas M; Skibber J; Ellis L; Eng C; Kopetz S; Maru DM
Cancer; 2013 Dec; 119(24):4231-41. PubMed ID: 24089344
[TBL] [Abstract][Full Text] [Related]
2. Patient Survival With ypT0N+ Following Neoadjuvant Therapy in Rectal Cancer.
Elshami M; Goldstone RN; Blaszkowsky LS; Cusack JC; Hong TS; Wo JY; Qadan M
Dis Colon Rectum; 2022 Oct; 65(10):1224-1231. PubMed ID: 35714358
[TBL] [Abstract][Full Text] [Related]
3. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
[TBL] [Abstract][Full Text] [Related]
4. Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.
Baucom RB; Maguire LH; Kavalukas SL; Geiger TM; Ford MM; Muldoon RL; Hopkins MB; Hawkins AT
Dis Colon Rectum; 2017 Dec; 60(12):1260-1266. PubMed ID: 29112561
[TBL] [Abstract][Full Text] [Related]
5. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
6. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
7. Tumor volume reduction assessed by planning computed tomography in patients with rectal cancer during preoperative chemoradiation: impact of residual tumor volume on the prediction of pathologic tumor regression.
Lee JA; Yang D; Yoon WS; Park YJ; Kim CY; Moon HY; Lee SI
Tumori; 2014; 100(2):158-62. PubMed ID: 24852859
[TBL] [Abstract][Full Text] [Related]
8. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
9. Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?
You KY; Gao YH
Cancer; 2014 Apr; 120(8):1281-2. PubMed ID: 24474633
[No Abstract] [Full Text] [Related]
10. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.
Shia J; McManus M; Guillem JG; Leibold T; Zhou Q; Tang LH; Riedel ER; Weiser MR; Paty PB; Temple LK; Nash G; Kolosov K; Minsky BD; Wong WD; Klimstra DS
Am J Surg Pathol; 2011 Jan; 35(1):127-34. PubMed ID: 21164296
[TBL] [Abstract][Full Text] [Related]
11. Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?
Maru DM; Agarwal AA; Hu CY; Chang GJ
Cancer; 2014 Apr; 120(8):1282. PubMed ID: 24474599
[No Abstract] [Full Text] [Related]
12. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
[TBL] [Abstract][Full Text] [Related]
13. Baseline T Classification Predicts Early Tumor Regrowth After Nonoperative Management in Distal Rectal Cancer After Extended Neoadjuvant Chemoradiation and Initial Complete Clinical Response.
Habr-Gama A; São Julião GP; Gama-Rodrigues J; Vailati BB; Ortega C; Fernandez LM; Araújo SEA; Perez RO
Dis Colon Rectum; 2017 Jun; 60(6):586-594. PubMed ID: 28481852
[TBL] [Abstract][Full Text] [Related]
14. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer-a Large Single-Center Experience.
Dinaux AM; Amri R; Bordeianou LG; Hong TS; Wo JY; Blaszkowsky LS; Allen JN; Murphy JE; Kunitake H; Berger DL
J Gastrointest Surg; 2017 Jul; 21(7):1153-1158. PubMed ID: 28386670
[TBL] [Abstract][Full Text] [Related]
16. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
[TBL] [Abstract][Full Text] [Related]
17. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome.
Shia J; Guillem JG; Moore HG; Tickoo SK; Qin J; Ruo L; Suriawinata A; Paty PB; Minsky BD; Weiser MR; Temple LK; Wong WD; Klimstra DS
Am J Surg Pathol; 2004 Feb; 28(2):215-23. PubMed ID: 15043311
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Positive Circumferential Resection Margin in Rectal Cancer: A Current Audit of the National Cancer Database.
Simon HL; de Paula TR; Profeta da Luz MM; Kiran RP; Keller DS
Dis Colon Rectum; 2021 Sep; 64(9):1096-1105. PubMed ID: 33951688
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
Park IJ; You YN; Agarwal A; Skibber JM; Rodriguez-Bigas MA; Eng C; Feig BW; Das P; Krishnan S; Crane CH; Hu CY; Chang GJ
J Clin Oncol; 2012 May; 30(15):1770-6. PubMed ID: 22493423
[TBL] [Abstract][Full Text] [Related]
20. Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response.
You KY; Huang R; Zhang LN; Ding PR; Xiao WW; Qiu B; Chang H; Zeng ZF; Pan ZZ; Gao YH
J Cancer Res Clin Oncol; 2015 Apr; 141(4):719-28. PubMed ID: 25296560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
